[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 11, Issue 1 (Int J Mol Cell Med (In Press) 2022) ::
Int J Mol Cell Med 2022, 11(1): 0-0 Back to browse issues page
Comparison of a Suggested Model of Fibrosis in Human Dermal Fibroblasts by Serum from Systemic Sclerosis Patients with Transforming Growth Factor β Induced in vitro Model
Elnaz Dadashzadeh1 , Marie Saghaeian Jazi1 , Nafiseh Abdolahi2 , Saeed Mohammadi 3, Mohsen Saeidi4
1- Stem Cell Research center, Golestan University of Medical Sciences, Gorgan, Iran.
2- Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
3- Stem Cell Research center, Golestan University of Medical Sciences, Gorgan, Iran. , s.mohammadi@goums.ac.ir
4- Department of Medical Immunology, Golestan University of Medical Sciences, Gorgan, Iran.
Abstract:   (787 Views)
Systemic sclerosis (SSc) is a chronic autoimmune disease, featuring fibrosis in multiple organs. The serum from SSc patients contain inflammatory mediators, contributing to SSc pathogenesis and could be used to develop cell culture models. Here, we compared the fibrotic effects of serum samples from SSc patients with TGFβ1 on human dermal fibroblasts (HDFs). HDF cells were cultured in four different culture media supplementations; 10% SSc serum, 10% healthy human serum, 10% fetal bovine serum  or 10% FBS supplemented with 10 ng/ml human TGFβ. The collagen content in cell layers was measured by spectrophotometric Picro-Sirius red staining. The mRNA expression of α-SMA, COL I and III, TGFβ1, arginase and E-Cadherin genes were determined by real time RT-PCR. TGF-β1 levels in cell culture supernatants were measured using ELISA. Cell layer collagen content was significantly increased following TGF-β1 treatment, compared with FBS group and SSc serum treatment in comparison with healthy controls. Although not statistically significant, the mRNA expression of α-SMA, COLI and III, TGFβ1, and arginase increased upon TGF-β1 treatment in comparison with FBS group, and in SSc serum treatment group in comparison with healthy controls. E-Cadherin decreased following TGF-β1 treatment and SSc serum treatment in comparison with their counterparts. TGF-β1 levels increased in cell culture supernatants of HDF cells exposed to TGF-β1 and SSc serum. An in vitro model of SSc serum-induced fibrosis using human HDF cells was evaluated in comparison to the TGF-β1 fibrosis induced model and data suggested that it may be used in documenting the role of pro-fibrotic factors in serum or plasma from SSc patients.

Keywords: Fibrosis, human dermal fibroblast, systemic sclerosis, autoimmune disease, TGF-β
Full-Text [PDF 529 kb]   (218 Downloads)    
Type of Study: Original Article | Subject: Cell Biology
Received: 2021/11/1 | Accepted: 2022/06/7 | Published: 2022/06/20
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dadashzadeh E, Saghaeian Jazi M, Abdolahi N, Mohammadi S, Saeidi M. Comparison of a Suggested Model of Fibrosis in Human Dermal Fibroblasts by Serum from Systemic Sclerosis Patients with Transforming Growth Factor β Induced in vitro Model. Int J Mol Cell Med. 2022; 11 (1)
URL: http://ijmcmed.org/article-1-1794-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 1 (Int J Mol Cell Med (In Press) 2022) Back to browse issues page
International Journal of Molecular and Cellular Medicine (IJMCM) International Journal of Molecular and Cellular Medicine (IJMCM)
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4460